{"groups":[{"description":"Erlotinib 150 mg by mouth daily for 3 weeks followed by cystectomy within 24 hours of the last dose.","id":"FG000","title":"Pre-surgical Erlotinib Treatment"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"34"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"31"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Erlotinib treatment milestone: Three participants decided to not start the study medication.","recruitmentDetails":"Recruitment began 6/9/2008 and concluded on 12/19/2011 in the medical clinic. Diagnosis of invasive transitional cell carcinoma in the bladder, upper tract or urethra tumors were required for participants who were candidates for cystectomy to be considered. Participants with high-risk features were generally excluded."}